News & SEC Filings

View the latest news and SEC filings

News

LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to its proposed acquisition by MSD (tradename of Merck &

Transaction expected to close on October 7, 2025 LONDON, U.K., and RALEIGH, N.C., Sept. 24, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a definitive agreement on July 8, 2025 relating to

Posters support Ohtuvayre ® (ensifentrine) as a first-in-class selective dual inhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., Sept. 16, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on

RAHWAY, N.J. & RALEIGH, N.C.–( BUSINESS WIRE )– MSD (tradename of Merck & Co., Inc., Rahway, N.J. USA) and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today announced that the companies have entered into a

SEC Filings

Date Form Filing Group

December 27, 2022

An amendment to a SC 13D filing

SC 13D/A

Other

December 21, 2022

Statement of changes in beneficial ownership of securities

4

3,4,5

December 21, 2022

Statement of changes in beneficial ownership of securities

4

3,4,5

December 20, 2022

Report of unscheduled material events or corporate event

8-K

Current Reports

November 15, 2022

Securities offered to employees pursuant to employee benefit plans

S-8

Registration Statements

November 9, 2022

Quarterly report which provides a continuing view of a company’s financial position

10-Q

Quarterly Filings

November 9, 2022

Report of unscheduled material events or corporate event

8-K

Current Reports

November 3, 2022

Statement of changes in beneficial ownership of securities

4

3,4,5

November 3, 2022

Statement of changes in beneficial ownership of securities

4

3,4,5

Developing novel therapeutics for respiratory diseases

Verona Pharma (Nasdaq:VRNA) is focused on delivering our strategy and creating value for shareholders.

Close up of female doctor hold woman patient hands help on personal therapy session, psychologist or counselor show understanding and care, support depressed suffering client on treatment